

## Press Release

### Apogenix to Present at Five Upcoming International Conferences

**Heidelberg, Germany, October 18, 2018** – Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that company representatives will attend several upcoming international conferences. In a total of five presentations, Apogenix will give updates on its hexavalent TNF superfamily receptor agonists (HERA-ligands) as well as its phase III-ready lead drug candidate asunercept.

**Joint BioRN & Ci3 Annual Conference 2018: Immunotherapy and beyond – The next generation of cancer treatment** (October 25, 2018)

Venue: Merck KGaA, Darmstadt, Germany

**Presentation on October 25, 2:55 pm:** “Apogenix’ TNFR-Mediated Signaling Modulators – Innovative Immuno-Oncology Therapeutics”

Presenter: Thomas Hoeger, Ph.D., CEO

**World Immunotherapy Congress 2018** (October 29 – 31, 2018)

Venue: Basel Congress Center, Basel, Switzerland

**Presentation on October 30, 3:35 pm:** “Hexavalent TNFR-SF Agonists for Cancer Immunotherapy: HERA-CD40L, HERA-CD27L and Beyond”

Presenter: Oliver Hill, Ph.D., VP Molecular Biology/Protein Engineering

**BIO-Europe** (November 5 – 7, 2018)

Venue: Bella Center Copenhagen, Copenhagen, Denmark

Attendees: Thomas Hoeger, Ph.D., CEO; Juergen Gamer, Ph.D., VP Business Development

**SITC 33rd Annual Meeting** (November 7 – 11, 2018)

Venue: Walter E. Washington Convention Center, Washington, D.C., USA

**Presentation on November 11, 8:05 – 10:30 am:** “Immuno-oncology tHERApY with HERA-GITRL: the novel hexavalent human G1TR agonist activates T cells and promotes anti-tumor efficacy independent of Fc-functionality” (Session: Next Generation Bispecifics and Antibody-Like Molecules)

Presenter: David Richards, Ph.D., Head of Immunology

**10th Annual PEGS Europe** (November 12 – 16, 2018)

Venue: Lisbon Congress Center, Lisbon, Portugal

**Presentation on November 15, 4:00 pm:** “HERA: Engineering Next-Generation TNFR-SF Agonists for Cancer Immunotherapy”

Presenter: Oliver Hill, Ph.D., VP Molecular Biology/Protein Engineering

**SNO 23rd Annual Meeting and Education Day** (November 15 – 18, 2018)

Venue: Marriott Hotel, New Orleans, LA, USA

**Poster Presentation on November 16, 7:30 – 9:30 pm:** “Asunercept plus radiotherapy in relapsed glioblastoma. Update on five years overall survival of study NCT01071837 and development of a Population-PK - Tumor Growth Inhibition - Survival Model” (Poster #ATIM-13)

Presenter: Harald Fricke, M.D., CMO

## About Apogenix

Apogenix is a private company developing innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The Heidelberg, Germany-based company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor (TNF) superfamily-dependent signaling pathways, thereby restoring the immune response against tumors. Checkpoint inhibitor asunercept, the company's lead immuno-oncology candidate, is in late-stage clinical development. In 2017, asunercept received PRIME (PRiority MEdicines) designation by the European Medicines Agency (EMA) for the treatment of glioblastoma. Based on its proprietary technology platform for the construction of novel hexavalent TNF superfamily receptor agonists (HERA-ligands), Apogenix develops CD40, CD27, GITR, HVEM, 4-1BB, and OX40 receptor agonists for cancer immunotherapy.

In 2015, asunercept was exclusively licensed to CANbridge Life Sciences for the development and commercialization for the treatment of glioblastoma in China, Macao, Hong Kong, and Taiwan. CANbridge has received approval by the China Food and Drug Administration for a pivotal phase II/III trial with asunercept (CAN008) in glioblastoma in China. The HERA-TRAIL receptor agonist program was partnered with AbbVie in 2014. In 2017, AbbVie initiated a phase I trial with this HERA-TRAIL receptor agonist (ABBV-621) in patients suffering from solid tumors, non-Hodgkins's lymphoma, or acute myeloid leukemia.

## Contacts

Thomas Hoeger, Ph.D., CEO  
Juergen Gamer, Ph.D., VP Business Development  
Apogenix AG  
Phone: +49 6221 58608-0  
E-Mail: [contact@apogenix.com](mailto:contact@apogenix.com)  
Web: [www.apogenix.com](http://www.apogenix.com)

## Media Contacts

Katja Arnold  
Andreas Jungfer  
MC Services AG  
Phone: +49 89 210228-0  
E-Mail: [apogenix@mc-services.eu](mailto:apogenix@mc-services.eu)